Tag:
tasocitinib
Latest Headlines
Latest Headlines
Pfizer's blockbuster RA hopeful clears a Ph3 hurdle
Pfizer ( $PFE ) has some upbeat Phase III data to report this morning. The pharma giant says that its oral JAK inhibitor tofacitinib--which recently underwent a name change from tasocitinib--hit its
Pfizer's ($PFE) RA pill tasocitinib posts blockbuster PhIII results
One of the most closely watched drugs in Pfizer's ( $PFE ) late-stage pipeline has cleared a pair of key hurdles, hitting two primary endpoints for rheumatoid arthritis while failing to overcome a
Pfizer's tasocitinib for psoriasis shows Phase II promise
Pfizer is touting results from a Phase II trial of tasocitinib (CP-690,550), an oral JAK inhibitor for moderate to severe plaque psoriasis. The drug is designed to block enzymes that play a key role
